Global Ankylosing Spondylitis Market Outlook to 2027: High Treatment Cost and Lack of Skilled Surgeons and Physiotherapists are Hampering Market Growth

Dublin, Nov. 04, 2020 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to's offering.

Global Ankylosing Spondylitis Market accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027, growing at a CAGR of 10.3% during the forecast period.

Rising prevalence of Ankylosing Spondylitis, growing awareness about diagnostics and treatments for the disease. Additionally, government initiatives and getting better healthcare infrastructure are the major factors propelling the market growth. However, the huge cost of treatment and lack of skilled surgeons and physiotherapists are hampering the market growth.

Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a kind of arthritis, in which spine bones grow or fuse together, causing the spine to turn into rigid. Symptoms of ankylosing spondylitis comprise pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.

Based on the drugs, the humira segment is going to have a lucrative growth during the forecast period due to it's a prescription medicine used to reduce the signs and symptoms of ankylosing spondylitis in adults. Humira can help to reduce the back pain, stiffness of AS, low cost and high efficiency.

By geography, North America is going to have a lucrative growth during the forecast period due to the more prevalence of the disease and amplified adoption of ankylosing spondylitis treatment options in the region. In addition, technological developments are driving ankylosing spondylitis treatment in this region.

Some of the key players profiled in the Ankylosing Spondylitis Market include Abbvie, Amgen, boehringer Ingelheim, bristol-Myers Squibb, Celgene, Celltrion, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc., Merck & Co, Novartis AG, Pfizer, Regeneron Pharmaceuticals, Sanofi, Shanghai Pharmaceuticals and UCB, Inc.

What the report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2018, 2019, 2020, 2024, and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and Recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Key Topics Covered:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End-user Analysis
3.8 Emerging Markets
3.9 Impact of COVID-19

4 Porters Five Forces Analysis

5 Global Ankylosing Spondylitis Market, By Molecule Type
5.1 Introduction
5.2 Biologics
5.3 Biosimilars
5.4 Small Molecules

6 Global Ankylosing Spondylitis Market, By Route of Administration
6.1 Introduction
6.2 Oral
6.3 Parenteral

7 Global Ankylosing Spondylitis Market, By Dosage Form
7.1 Introduction
7.2 Liquid
7.3 Solid

8 Global Ankylosing Spondylitis Market, By Drug
8.1 Introduction
8.2 Cimzia
8.3 Cosentyx
8.4 Enbrel
8.5 Humira
8.6 Remicade
8.7 Simponi

9 Global Ankylosing Spondylitis Market, By Drug Type
9.1 Introduction
9.2 Anti-Inflammatory Drugs
9.3 COX Inhibitors
9.4 Disease-Modifying Anitrheumatic Drugs (DMARDs)
9.5 Immunosuppressive Drugs
9.6 JAK Inhibitors
9.7 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
9.8 Steroids
9.9 TNF Inhibitors
9.10 IL-17 Inhibitors

10 Global Ankylosing Spondylitis Market, By Treatment Type
10.1 Introduction
10.2 Medication
10.3 Surgery
10.4 Therapy

11 Global Ankylosing Spondylitis Market, By Application
11.1 Introduction
11.2 Adults
11.3 Juveniles

12 Global Ankylosing Spondylitis Market, By End-user
12.1 Introduction
12.2 Hospital
12.3 Care Home
12.4 Clinic

13 Global Ankylosing Spondylitis Market, By Geography

14 Key Developments
14.1 Agreements, Partnerships, Collaborations and Joint Ventures
14.2 Acquisitions & Mergers
14.3 New Product Launches
14.4 Expansions
14.5 Other Key Strategies

15 Company Profiling
15.1 Abbvie
15.2 Amgen
15.3 Boehringer Ingelheim
15.4 Bristol-Myers Squibb
15.5 Celgene
15.6 Celltrion
15.7 Eisai
15.8 Eli Lilly and Company
15.9 F. Hoffmann-La Roche
15.10 Janssen Pharmaceuticals
15.11 Johnson & Johnson Services, Inc.
15.12 Merck & Co
15.13 Novartis AG
15.14 Pfizer
15.15 Regeneron Pharmaceuticals
15.16 Sanofi
15.17 Shanghai Pharmaceuticals
15.18 UCB, Inc.

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Contact Data